Immunotherapy Toxicities: Uncovering Predictive Markers for Early Signs of Immune Related Toxicity

Immune checkpoint inhibitors and other immunotherapies/ cancer vaccines have revolutionised the oncology landscape, offering durable responses in cancers previously associated with limited options. However, these treatments can provoke immune-related adverse events (irAEs) affecting multiple organ systems, sometimes unpredictably. Current clinical predictors remain insufficient to anticipate which patients will develop significant toxicity, and conventional monitoring often detects irAEs only after symptoms become clinically overt. At the same time, quality-of-life (QoL) and patient-reported outcomes provide valuable insights into early symptom evolution but are inconsistently collected or integrated with biological data.Advances in single-cell technologies and immune-profiling now allow deep characterisation of the cellular responses underpinning irAEs. Combining these tools with structured QoL analytics offers a powerful approach to uncovering novel biomarkers and improving toxicity prediction.The primary goal of this topic is to identify and characterise biomarkers that can predict immune-related toxicities associated with immune checkpoint inhibitors and other modern immunotherapies. By integrating patient-reported quality-of-life (QoL) metrics with molecular, cellular, and computational analyses—including single-cell omics—we aim to foster approaches that detect toxicity earlier, stratify risk more accurately, and offer real-time insights into patient well-being.A crucial objective is to bridge the gap between translational science and clinical practice. This involves encouraging multidisciplinary work that aligns biological signatures with meaningful patient experiences to create more holistic and responsive toxicity-prediction models. Ultimately, this Research Topic seeks to support the development of precision-based tools that improve the tolerability, safety, and personalisation of immunotherapy, enabling clinicians to make more informed treatment decisions while minimising patient harm.We invite multidisciplinary contributions focused on advancing the prediction, understanding, and management of immune-related adverse events (irAEs) associated with cancer immunotherapy. We particularly encourage studies that integrate quality-of-life (QoL) and patient-reported outcome measures (PROMs) with molecular and cellular biomarkers, including single-cell transcriptomics, high-dimensional immune profiling, proteomics, metabolomics, and computational modelling. Themes of interest include mechanistic insights into irAE pathogenesis, biomarker discovery, digital health approaches for early toxicity detection, longitudinal patient monitoring, and the development of predictive algorithms or risk-stratification tools. We welcome a range of article types, including original research, systematic and mini-reviews, brief research reports, perspectives, hypotheses and theory papers, and methods-focused submissions. Contributions spanning clinical oncology, immunology, computational biology, data science, and translational research are especially encouraged. Authors should aim to advance personalised toxicity prediction and improve the safety and patient-centred delivery of immunotherapy. Topic editors: Farasat Kazmi, Brent O'Carrigan, James Jones, Anna Olsson-Brown Source: https://www.frontiersin.org/research-topics/77063/immunotherapy-toxicities-uncovering-predictive-markers-for-early-signs-of-immune-related-toxicity